VAL.L

ValiRx plc [VAL.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VAL.L Stock Summary

Top 10 Correlated ETFs

VAL.L

Top 10 Correlated Stocks

VAL.L

In the News

VAL.L Financial details

Company Rating
-
Market Cap
4.83M
Income
-4.18M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
03 Jun 2024
P/E
-1.83
Forward P/E
-
PEG
-0.15
P/S
-
P/B
1.09
P/C
-
P/FCF
-4.41
Quick Ratio
8.92
Current Ratio
11.48
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.05
EPS next Y
-
EPS next Q
-
EPS this Y
30.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-33.12%
-
-
-
-
SMA20
-10.91%
SMA50
-25.76%
SMA100
-70.12%
Inst Own
-
Inst Trans
-
ROA
-61%
ROE
-63%
ROC
-0.67%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.4-15.0
52W High
-96.67%
52W Low
-83.33%
RSI
44.5
Rel Volume
0.71
Avg Volume
669.66K
Volume
476.25K
Perf Week
0%
Perf Month
-20%
Perf Quarter
-67.32%
Perf Half Y
-68.75%
-
-
-
-
Beta
0.632
-
-
Volatility
0.01%, 0.05%
Prev Close
5.26%
Price
0.5
Change
9.77%

Something similar

Top by Market Cap
M&M.NS
GOOG
BRYN.DE
0YXG.L
3V64.DE
Top Correlated ETFs
HYGN.L
CHIP.SW
3109.HK
SEMG.L
HDRO.L
Top Correlated Stocks
1468.HK
1942.HK
6968.HK
9103.TW
EUA.L
Similar Market Cap
DIVA
DIVD
SNOA
WINT
ELV.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 669.66K
  • Market Capitalization 4.83M
  • Employee 8
  • CEO Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D.
  • Headquarters Hatfield,GB
  • IPO Date 2002-01-07
  • Website https://www.valirx.com

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.